Iris Melanoma

Back

Overview

Iris nevi and melanomas are the most common primary tumors of the iris, with an incidence ranging from 50-70% of all iris tumors; of these, 10-24% may be melanomas. Melanomas arise from malignant proliferation of the neuroectodermally derived iris stromal melanocytes, which replaces the normal iris stromal architecture. While melanoma is the most common primary malignancy of the iris, it comprises only 3%-10% of all uveal melanomas.[1]  Considerable controversy exists regarding the histopathologic classification and the malignant potential of iris melanomas.

See The Case of the Middle-Aged Woman with Sudden Unilateral Vision Loss, a Critical Images slideshow, to help identify and treat malignant intraocular tumors.

See Ciliary Body Melanoma, Choroidal Melanoma, and Conjunctival Melanoma for complete information on these topics.

Pathophysiology and Etiology

Most iris melanomas are believed to arise from a preexisting nevi. Epidemiologic studies suggest that high levels of solar ultraviolet B (UV-B) radiation plays a role in the pathogenesis of iris melanomas.[2] Loss of chromosome 3, as well as loss of chromosomal region 9p21 (entails tumor suppressor gene CDKN2A), plays a role in iris melanoma.[3]

Epidemiology

Clinical and histopathologic studies show that only 13%-25% of all suspected iris melanomas actually meet the criteria for melanomas.

The mean age-adjusted incidence of uveal melanoma in the United States was 4.3 per million population between 1973 and 1997. Most cases (97.8%) were reported to occur in whites. It is more common in males than in females. Prevalence does not appear to vary by geographic location.[4]

 Rates of transformation of a suspicious iris nevus to melanoma are reported at 4% in 10 years and 11% by 20 years.[5] In a study surveying 3680 iris tumors based on patient age at presentation, Shields et al found that nevus (42%), iris pigment epithelium (IPE) cyst (19%), and melanoma (17%) were the most common specific diagnoses at all ages.[6]

Clinical Presentation

Patient history

Many patients with iris melanoma provide a history of a nevus existing since childhood that has suddenly undergone rapid growth. This may be noticed by the patient or during a routine eye examination. Patients may present because of cosmetic concerns. Some patients may experience pain due to increased intraocular pressure or a change in vision caused by cataract development.

Physical examination

Iris melanomas may be circumscribed or diffuse. Circumscribed melanomas have a nodular shape, and almost 80% arise in the inferior half of the iris (see image below).[7]  They vary in size, shape, and clinical behavior. They are typically yellow, tan, or brown in color with a flat or rounded anterior contour.[1]  They can grow anteriorly into the anterior chamber or posteriorly into the posterior chamber, usually being limited by the lens and giving a “lion’s paw” appearance on ultrasonographic biomicroscopy (UBM).



View Image

Inferior Iris melanoma of the left eye that is pushing the pupil superiorly and nasally and distorting the normal appearance of the iris.

Diffuse melanomas present differently from circumscribed melanomas, usually as a unilateral dark iris (acquired heterochromia) without focal thickening.[8] Diffuse melanoma may also be associated with glaucoma, which tends to respond poorly to medical management and causes severe disc cupping and functional loss. Diffuse melanomas also tend to be of the epithelioid cell type and carry a higher risk of metastasis than do circumscribed melanomas. Distant metastasis occurs in 13% of patients with diffuse iris melanomas.[8]

General signs indicative of malignant transformation include rapid growth of the lesion and the development of prominent blood vessels.

Ring melanomas involve more than two thirds of the angle and have associated glaucoma. Tapioca melanomas are multifocal nodules projecting into the anterior chamber that may be associated with glaucoma.

According to Shields, criteria for a clinical diagnosis of melanoma are as follows:[9]

Ciliary body involvement is associated with a higher incidence of malignancy. Medial location and pigment dispersion onto the iris or the angle structures are associated with tumor growth.

Shields et al described clinical features predictive of growth from iris nevus to iris melanoma based on evaluation of 1611 eyes at an ocular oncology center. They state that the risk factors for growth may be identified by the following:[10]

A thorough ophthalmologic examination, including transillumination and indirect examination with scleral depression, is essential for differentiating among iris cysts, primary iris tumors, and primary ciliary body melanomas.

Gonioscopy and UBM of the entire ciliary body must also be performed to rule out involvement before any therapeutic decisions are made.

Complications

Potential complications of iris melanoma include the following:

Untreated iris melanoma can lead to complications such as recurrent hyphema and glaucoma with irreversible optic nerve damage, which is why treatment of slow-growing iris melanoma must be considered to prevent complications.[11]

Differential Diagnoses

The differential diagnoses of iris melanomas include the following:

Imaging Studies

Sequential Photography

Sequential photographs of iris lesions are extremely helpful for monitoring the lesions’ size and growth and are done usually prior to dilation.

Ultrasonographic Biomicroscopy

UBM can be extremely helpful in differentiating solid iris masses from iris cysts. Melanomas involving the anterior chamber angle can also invade the ciliary body. Thus, in these tumors, gonioscopy and UBM of the ciliary body is critical. The anterior chamber angle can also be viewed, and ciliary body involvement can be evaluated. Nodular melanomas with posterior extension delimited by the lens may show a “lion’s paw” appearance on UBM. UBM has recently been used to help monitor the characteristics of these lesions after brachytherapy.[12]

B-scan Ultrasonography

B-scan ultrasonography can be helpful in visualizing the extension of the lesion and determining the level of variation in appearance. See the image below.



View Image

B-scan ultrasonogram of a patient with an iris melanoma showing a solid echogenic nodule.

Anterior Segment Optical Coherence Tomography

Anterior segment optical coherence tomography (AS-OCT) is superior to B-scan for imaging small lesions pertaining to the anterior iris, but B-scan is better for imaging larger iris lesions with posterior or ciliary body extension.[13]

Other Studies

Fluorescein angiography may show irregular vascular channels with late filling. However, this modality is rarely helpful and is usually not performed in clinical practice.

Diagnostic Procedures

Diagnostic procedures include the following:

A multicenter study by Khan et al gathered information on biopsy-proven melanoma of the iris. The study found that the melanomas were most often brown and located in the inferior quadrants of patients with light irides. Commonly associated with angle blunting and spindle cell histopathology, melanomas are usually small and unifocal.[15]

In a 2012 study, liver function testing was not helpful for the early diagnosis of metastatic uveal melanoma, although the high negative predictive value of such tests suggests that they might allow clinicians to reassure patients when test results are negative.[16]

Histologic Findings

Malignant melanocytic stromal proliferation disrupts the normal iris stromal architecture. The Callender classification divides iris melanomas into spindle A (benign) and spindle B (fascicular, mixed, epithelioid, and necrotic) types. The Jakobiec and Silbert classification categorizes the lesions as spindle cell melanoma, spindle and epithelioid melanoma, or epithelioid melanoma.[17] According to a modified Callender classification system, most reported iris melanomas in the literature are diagnosed as spindle cell melanoma.[18]

Small and unifocal melanomas are commonly associated with a spindle cell histopathology.[19]

There is evidence that the proliferation of melanocytes of the anterior iris surface and diffuse stromal invasion may be risk factors for local recurrence and metastasis.[20]

Treatment & Management

Medical care

Patients are observed closely with periodic slit-lamp examination, photographic documentation, and ultrasonographic biomicroscopy (UBM). Glaucoma can be controlled with medication if no tumor infiltration of the angle structures is present.

Surgical care

In general, sector iridectomy is performed for small tumors, and iridocyclectomy is performed to treat tumors that invade the angle. Other options include radiotherapy with a radioactive plaque (brachytherapy) or external proton-beam irradiation. Finally, enucleation may be required for diffusely growing tumors if radiotherapy is not possible.

The treatment of choice for growing lesions has typically been excision. Over the past 30 years, advances in microsurgical techniques and equipment have improved access to the iris and anterior chamber angle and have enabled more precise tumor resection with less trauma to the eye and less complications.

However, reports in the literature have described the successful treatment of iris melanomas with brachytherapy and proton-beam irradiation.

Excision is recommended if the lesion is impinging on the pupillary margin and interfering with vision or if secondary glaucoma is not controlled with medication. Excision should be considered if the lesion grows rapidly or encroaches on the chamber angle or if the fine-needle aspiration biopsy specimen shows malignant histology. Excision must be complete—either a sector iridectomy or an iridocyclectomy if the lesion encroaches on the chamber angle.

Plaque radiation therapy with palladium 103 (103Pd) has been used for these patients. Preliminary results show a high rate of success, with the most common complication being cataract formation in more than 75% of phakic patients.

Proton-beam therapy is an effective treatment for nonresectable iris melanomas. The major complications include cataract and glaucoma.[21]

Glaucoma filtration procedures should not be attempted in the setting of a potential iris melanoma, as they may lead to seeding of the tumor cells and metastases.

As an alternative to enucleation, whole anterior segment fractionated proton-beam radiotherapy has offered excellent local tumor control in diffuse iris melanoma. Given the limited alternatives, the rate of complications appears acceptable and visual function could be preserved in most patients during follow-up.[22]

Consultations

Iris melanoma usually needs to be treated in coordination with an ophthalmologist/oncologist, especially if a metastatic lesion is suspected. After surgery, patients must be monitored at least every 6 months for metastatic development.

Further outpatient care

Patients should receive follow-up care as needed. They need to be monitored periodically for lesion recurrence and metastatic development as warranted. In addition, the intraocular pressure should be monitored closely if the patient had developed secondary glaucoma due to the melanoma itself or the seeding of tumor through the angle.

Deterrence/prevention

Exposure to ultraviolet light should be minimized, as high levels of solar UV-B radiation has been a suggested etiology.

Prognosis

Most primary tumors of the iris are benign. The prognosis of iris melanoma is usually better than that of melanoma of the ciliary body and choroid, although there is no clear reason for this. A possible explanation is that iris melanoma is smaller than its posterior segment counterparts at the time of diagnosis.[23]

Prognosis is generally good in terms of survival. Young adults tend to have a smaller melanoma basal dimension and a lower rate of tumor-related metastasis and death than do older populations.[24]

The mortality rate ranges from 0%-11%, depending on the cell type, the presence or absence of metastases, and ciliary body involvement; in the absence of ciliary body involvement, the rate is 0%-3%. Metastatic rate according to cell type are 2.6% for spindle cell, 10.5% for mixed cell, and 6.9% for epithelioid cell type.[18]

Metastases occur in 2%-10% of all iris melanomas; a higher rate of metastasis is observed in cases of ciliary body involvement. Clinical features that may predict metastasis from iris melanoma include the following:[25]

Author

Buraa Kubaisi, MD, Research Fellow, Massachusetts Eye Research and Surgery Institute

Disclosure: Nothing to disclose.

Coauthor(s)

C Stephen Foster, MD, FACS, FACR, FAAO, FARVO, Clinical Professor of Ophthalmology, Harvard Medical School; Consulting Staff, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary; Founder and President, Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery Institution

Disclosure: Nothing to disclose.

Specialty Editors

Simon K Law, MD, PharmD, Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Disclosure: Nothing to disclose.

Christopher J Rapuano, MD, Professor, Department of Ophthalmology, Jefferson Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Hospital

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cornea Society, Allergan, Bausch & Lomb, Bio-Tissue, Shire, TearScience, TearLab<br/>Serve(d) as a speaker or a member of a speakers bureau for: Allergan, Bausch & Lomb, Bio-Tissue, TearScience.

Chief Editor

Hampton Roy, Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Disclosure: Nothing to disclose.

Additional Contributors

Courtney M Crawford, MD, FACS, Fellow, Vitreoretinal Surgery, New England Eye Center; Assistant Professor of Surgery, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Community Faculty, Vanderbilt Eye Institute, Vanderbilt University School of Medicine

Disclosure: Nothing to disclose.

Nadia K Waheed, MD, MPH, Assistant Professor of Ophthalmology, Tufts University School of Medicine; Consulting Staff, Department of Ophthalmology, New England Eye Center, Tufts Medical Center

Disclosure: Nothing to disclose.

Russell P Jayne, MD, Consulting Vitreoretinal Surgeon, The Retina Center at Las Vegas

Disclosure: Nothing to disclose.

References

  1. Shields JA, Shields CL. Intraocular Tumors. A Text and Atlas. Philadelphia, Pa: WB Saunders; 1992. 61-3.
  2. Michalova K, Clemett R, Dempster A, Evans J, Allardyce RA. Iris melanomas: are they more frequent in New Zealand?. Br J Ophthalmol. 2001 Jan. 85 (1):4-5. [Medline][View Abstract]
  3. Mensink HW, Vaarwater J, de Keizer RJ, de Wolff-Rouendaal D, Mooy CM, de Klein A, et al. Chromosomal aberrations in iris melanomas. Br J Ophthalmol. 2011 Mar. 95 (3):424-8. [Medline][View Abstract]
  4. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003 May. 110 (5):956-61. [Medline][View Abstract]
  5. Shields CL, Shields PW, Manalac J, Jumroendararasame C, Shields JA. Review of cystic and solid tumors of the iris. Oman J Ophthalmol. 2013 Sep. 6(3):159-64. [Medline][Full Text][View Abstract]
  6. Shields CL, Kancherla S, Patel J, et al. Clinical survey of 3680 iris tumors based on patient age at presentation. Ophthalmology. 2012 Feb. 119(2):407-14. [Medline][View Abstract]
  7. Rones B, Zimmerman LE. The prognosis of primary tumors of the iris treated by iridectomy. AMA Arch Ophthalmol. 1958 Aug. 60(2):193-205. [Medline][View Abstract]
  8. Demirci H, Shields CL, Shields JA, Eagle RC Jr, Honavar SG. Diffuse iris melanoma: a report of 25 cases. Ophthalmology. 2002 Aug. 109(8):1553-60. [Medline][View Abstract]
  9. Shields JA, Sanborn GE, Augsburger JJ. The differential diagnosis of malignant melanoma of the iris. A clinical study of 200 patients. Ophthalmology. 1983 Jun. 90(6):716-20. [Medline][View Abstract]
  10. Shields CL, Kaliki S, Hutchinson A, Nickerson S, Patel J, Kancherla S, et al. Iris nevus growth into melanoma: analysis of 1611 consecutive eyes: the ABCDEF guide. Ophthalmology. 2013 Apr. 120(4):766-72. [Medline][View Abstract]
  11. Chang MY, McCannel CA, McCannel TA. UNTREATED IRIS MELANOMA COMPLICATED BY HYPHEMA AND UNCONTROLLED GLAUCOMA RESPONSIVE TO IODINE-125 BRACHYTHERAPY. Retin Cases Brief Rep. 2016 Winter. 10 (1):44-7. [Medline][View Abstract]
  12. Torres VL, Allemann N, Erwenne CM. Ultrasound biomicroscopy features of iris and ciliary body melanomas before and after brachytherapy. Ophthalmic Surg Lasers Imaging. 2005 Mar-Apr. 36(2):129-38. [Medline][View Abstract]
  13. Hau SC, Papastefanou V, Shah S, Sagoo MS, Restori M, Cohen V. Evaluation of iris and iridociliary body lesions with anterior segment optical coherence tomography versus ultrasound B-scan. Br J Ophthalmol. 2015 Jan. 99 (1):81-6. [Medline][View Abstract]
  14. Finger PT, Milman T. Microincision, aspiration cutter-assisted multifocal iris biopsy for melanoma. Eur J Ophthalmol. 2016 May 26. 132(3):328-35. [Medline][View Abstract]
  15. Khan S, Finger PT, Yu GP, et al. Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol. 2012 Jan. 130(1):57-64. [Medline][View Abstract]
  16. Mouriaux F, Diorio C, Bergeron D, Berchi C, Rousseau A. Liver function testing is not helpful for early diagnosis of metastatic uveal melanoma. Ophthalmology. 2012 Aug. 119(8):1590-5. [Medline][View Abstract]
  17. Jakobiec FA, Silbert G. Are most iris "melanomas' really nevi? A clinicopathologic study of 189 lesions. Arch Ophthalmol. 1981 Dec. 99(12):2117-32. [Medline][View Abstract]
  18. Geisse LH, Robertson DM. Iris melanoma. Am J Ophthalmol. 1985. 99:638-48.
  19. Khan S, Finger PT, Yu GP, Razzaq L, Jager MJ, de Keizer RJ, et al. Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol. 2012 Jan. 130 (1):57-64. [Medline][View Abstract]
  20. Henderson E, Margo CE. Iris melanoma. Arch Pathol Lab Med. 2008 Feb. 132 (2):268-72. [Medline][View Abstract]
  21. Rundle P, Singh AD, Rennie I. Proton beam therapy for iris melanoma: a review of 15 cases. Eye (Lond). 2007 Jan. 21 (1):79-82. [Medline][View Abstract]
  22. Willerding GD, Cordini D, Hackl C, Karle B, Lakotka N, Foerster MH, et al. Proton beam radiotherapy of diffuse iris melanoma in 54 patients. Br J Ophthalmol. 2015 Jun. 99 (6):812-6. [Medline][View Abstract]
  23. Henderson E, Margo CE. Iris melanoma. Arch Pathol Lab Med. 2008 Feb. 132 (2):268-72. [Medline][View Abstract]
  24. Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 2012 Jul. 32 (7):1363-72. [Medline][View Abstract]
  25. Shields CL, Shields JA, Materin M, Gershenbaum E, Singh AD, Smith A. Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology. 2001 Jan. 108(1):172-8. [Medline][View Abstract]

Inferior Iris melanoma of the left eye that is pushing the pupil superiorly and nasally and distorting the normal appearance of the iris.

B-scan ultrasonogram of a patient with an iris melanoma showing a solid echogenic nodule.

Inferior Iris melanoma of the left eye that is pushing the pupil superiorly and nasally and distorting the normal appearance of the iris.

B-scan ultrasonogram of a patient with an iris melanoma showing a solid echogenic nodule.